Glucosamine therapy for knee osteoarthritis: Pharmacokinetic considerations

Roy D Altman

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.

Original languageEnglish (US)
Pages (from-to)359-371
Number of pages13
JournalExpert Review of Clinical Pharmacology
Volume2
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Knee Osteoarthritis
Glucosamine
Pharmacokinetics
Sample Size
Arthritis
Therapeutics
Salts
Clinical Trials
Pharmacology
Population

Keywords

  • Clinical trials
  • Crystalline glucosamine sulfate
  • Glucosamine hydrochloride
  • Knee osteoarthritis
  • Osteoarthritis
  • Osteoarthritis therapy
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Glucosamine therapy for knee osteoarthritis : Pharmacokinetic considerations. / Altman, Roy D.

In: Expert Review of Clinical Pharmacology, Vol. 2, No. 4, 2009, p. 359-371.

Research output: Contribution to journalArticle

@article{de3bd1f750ee4433ac22d5f84d5294a8,
title = "Glucosamine therapy for knee osteoarthritis: Pharmacokinetic considerations",
abstract = "Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.",
keywords = "Clinical trials, Crystalline glucosamine sulfate, Glucosamine hydrochloride, Knee osteoarthritis, Osteoarthritis, Osteoarthritis therapy, Pharmacokinetics",
author = "Altman, {Roy D}",
year = "2009",
doi = "10.1586/ecp.09.17",
language = "English (US)",
volume = "2",
pages = "359--371",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Glucosamine therapy for knee osteoarthritis

T2 - Pharmacokinetic considerations

AU - Altman, Roy D

PY - 2009

Y1 - 2009

N2 - Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.

AB - Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.

KW - Clinical trials

KW - Crystalline glucosamine sulfate

KW - Glucosamine hydrochloride

KW - Knee osteoarthritis

KW - Osteoarthritis

KW - Osteoarthritis therapy

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=70149088596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149088596&partnerID=8YFLogxK

U2 - 10.1586/ecp.09.17

DO - 10.1586/ecp.09.17

M3 - Article

C2 - 22112180

AN - SCOPUS:70149088596

VL - 2

SP - 359

EP - 371

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 4

ER -